

**CURRICULUM VITAE**  
**Powel H. Brown, M.D., PhD.**

**DATE OF BIRTH:** November 12, 1957

**PLACE OF BIRTH:** Van Nuys, California

**PROFESSIONAL ADDRESS:** Breast Center  
 Baylor College of Medicine  
 One Baylor Plaza, BCM 600  
 Houston, Texas 77030  
 Telephone: (713) 798-1609; Fax: (713) 798-1642  
 E-mail: [pbrown@breastcenter.tmc.edu](mailto:pbrown@breastcenter.tmc.edu)

**PRESENT ACADEMIC RANK AND POSITION: Professor with Tenure**

Primary Appointment: Department of Medicine, Division of Medical Oncology  
 Baylor College of Medicine, Houston, Texas

Secondary Appointment: Department of Molecular and Cellular Biology,  
 Baylor College of Medicine, Houston, Texas

Cancer Center Positions: Associate Director for Cancer Prevention;  
 Program Leader Cancer Prevention & Population Sciences  
 Baylor College of Medicine, Houston, Texas

Breast Center Positions: Associate Director of Research, Baylor Breast Center  
 Baylor College of Medicine, Houston, Texas

**EDUCATION:** 1979, University of North Carolina at Chapel Hill, B.S., Summa Cum Laude  
 1984, New York University, Ph.D.  
 1985, New York University, M.D.

**POST-GRADUATE TRAINING:**

Internship/ Internal Medicine, 1985-1988  
 Residency Duke University Medical Center, Durham, NC

Clinical Medical Oncology Fellowship, 1988-1991  
 Fellowship Clinical Oncology Program,  
 National Cancer Institute, NIH

Research Post-Doctoral Research Fellowship, 1989-1991  
 Fellowship Laboratory of Dr. Michael Birrer  
 Navy Medical Oncology Branch, NCI

**BOARD CERTIFICATION**

Diplomate of the National Board of Medical Examiners, July 1986  
 Diplomate, American Board of Internal Medicine, September 1988  
 Diplomate, American Board of Internal Medicine, Subspecialty in Medical Oncology, November 1991

Diplomate, American Board of Internal Medicine, Subspecialty in Medical Oncology, Recertification, 2000.

**MEDICAL LICENSURE**

Texas License No. K1377

**ACADEMIC AWARDS**

National Science Foundation Research Fellowship, 1978  
Kenan Chemistry Award for Outstanding Research, 1979  
Phi Beta Kappa, 1979  
National Institute of Health Medical Scientist Training Fellowship, 1979-1985  
Alpha Omega Alpha National Medical Honorary Society, 1984  
Bertram Gesner Memorial Award for Excellence in Immunology Research, 1985  
American College of Physicians Clinical Vignette Winner, 1988  
Public Health Service Outstanding Achievement Medal, 1992  
Public Health Service Citation Award, 1993  
Career Development Award, SPORE in Breast Cancer, 1996  
V Foundation Scholar, 1997

**MILITARY SERVICE**

1992-1995 Commander, U.S. Public Health Service,  
National Cancer Institute, National Institutes of Health, Bethesda, MD

1991-1992 Lieutenant Commander, U.S. Public Health Service,  
National Cancer Institute, National Institutes of Health, Bethesda, MD

1990-1991 Lieutenant, U.S. Public Health Service,  
National Cancer Institute, National Institutes of Health, Bethesda, MD

**PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS**

1999-2005 Associate Professor with Tenure, Departments of Medicine, and Molecular and Cellular Biology,  
Baylor College of Medicine, Houston, Texas

1998-1999 Associate Professor with Tenure, Dept. of Medicine, Div. of Medical Oncology  
The University of Texas Health Science Center at San Antonio, Texas

1995-1999 Co-Director, Cancer Prevention and Health Promotion Program, San Antonio Cancer Institute  
The University of Texas Health Science Center at San Antonio, Texas

1995-1998 Assistant Professor, Department of Medicine, Division of Medical Oncology  
The University of Texas Health Science Center at San Antonio, Texas

1995-1998 Assistant Professor, Department of Molecular Medicine, School of Biomedical Sciences, The  
University of Texas Health Science Center at San Antonio, Texas

1991-1995 Investigator, Molecular Mechanisms Section, Biomarkers and Prevention Research Branch,  
Division of Cancer Prevention and Control  
National Cancer Institute, National Institutes of Health, Bethesda, MD

1993-1995 Assistant Professor, Uniformed Services University of the Health Sciences, Bethesda, MD

1991-1995 Attending Physician, Division of Medical Oncology, National Cancer Institute, Bethesda Naval Hospital, Bethesda, MD

1988-1991 Clinical Associate, Clinical Oncology Program, National Cancer Institute  
National Institutes of Health, Bethesda, MD

### **PROFESSIONAL MEMBERSHIPS AND SOCIETIES**

Member, American Society of Preventive Oncology, 2001-present  
Chair, Translational Working Group, Cancer Genetics Network, 2000-present  
Member, National Surgical Breast and Bowel Adjuvant Project Group, 1999-present  
Member, Cancer Genetics Network, 1998 - present  
Co-Chair, Clinical Cancer Research Committee, Southwest Oncology Group, 1999-present  
Co-Chairman, Cancer Control Research Committee, Southwest Oncology Group, 1997-present  
Member, Texas Cancer Genetics Consortium, 1997-present  
Member, American Society of Clinical Oncology, 1998-present  
Member, Southwest Oncology Group, 1996-present  
Member, San Antonio Cancer Institute, 1995-present  
Member, American Association for Cancer Research, 1991-present  
Member, American Association for the Advancement of Science, 1991-present

### **PROFESSIONAL ACTIVITIES**

#### **Leadership Positions**

2006-present Co-Director of MD-PhD Program  
Baylor College of Medicine

2003-present Associate Director of Research  
Breast Center, Baylor College of Medicine

2003-present Associate Director of Cancer Prevention  
The Cancer Center, Baylor College of Medicine

2003-present Program Director Cancer Prevention and Population Sciences Program,  
The Cancer Center, Baylor College of Medicine

2000-2003 Chair, Translational Working Group, Cancer Genetics Network

1999-present Director, Cancer Prevention Section  
Breast Center, Baylor College of Medicine

1997-present Co-Chairman, Cancer Control Research Committee  
Southwest Oncology Group (SWOG)

1996-1999 Co-Director, Cancer Prevention and Health Promotion Program  
San Antonio Cancer Institute

1997 Chairman, Cancer Prevention Workshop

Sixth Annual Symposium for Cancer Research  
San Antonio Cancer Institute

1993 Chairman, Tumor Biology Group, Workshop on the Prevention of Lung Cancer  
International Association for the Study of Lung Cancer

**Committee Memberships**

2003-present Member, American Society of Clinical Oncology (ASCO) Scientific Programs Committee  
2003-present Member, Early Detection Research Network (EDRN) Consulting Committee (NCC)  
2002-present Baylor College of Medicine, IACUC Animal Committee  
2002-present T32 Training Grant Operating Committee, Baylor College of Medicine  
2001-present Medical Student Research Training Program, Faculty Operating Committee  
2000-present Southwest Oncology Group (SWOG) Co-chair, Cancer Control Research Committee  
1999-present MD/PhD Medical Student Training Program, Faculty Operating Committee  
1999-present Member, Steering Committee, SELECT Prostate Cancer Prevention Trial  
1998-present Member, Steering Committee, PCPT Prostate Cancer Prevention Committee, SWOG  
1998-present Member, Steering Committee, Texas Cancer Genetics Consortium  
1997-1999 Member, San Antonio Breast Cancer Symposium Planning Committee  
1997-1999 Member, Clinical Prevention Committee, American Association for Cancer Research  
1998-1999 Member, Institutional Intellectual Property Advisory Committee  
University of Texas Health Science Center at San Antonio  
1996-1999 Member, San Antonio Cancer Institute Executive Committee  
University of Texas Health Science Center at San Antonio  
1996-1998 Member, Radiation Safety Committee  
University of Texas Health Science Center at San Antonio

**Peer Review Boards**

2003-present NIH Study Section, Tumor Cell Biology (Full Member)  
2002-present NIH Study Section Subcommittee IRG-F, Manpower and Training (Full Member)  
2001-2002 NIH Study Section, Metabolic Pathology (Ad hoc member 2001-2002; Full Member 2002)  
2001-2002 NIH Study Section, IRG-F, Manpower Study Section (Ad hoc member)  
2001-2002 Epidemiology Study Section Member  
DOD/Army USAMRMC Breast Cancer Research Program  
1997-1999 Grant Proposal Reviewer, M.D. Anderson Cancer Prevention Program  
1996-1998 Molecular Biology 4 Study Section Member,  
DOD/Army USAMRMC Breast Cancer Research Program  
1995 Molecular Biology 1 Study Section Member,  
DOD/Army USAMRMC Breast Cancer Research Program  
1995-1999 VA Merit Review Board (Ad hoc Member)  
1994-1996 National Science Foundation (Ad hoc Member)

**Editorial Boards**

2002-present Senior Editor, *Cancer Epidemiology, Biomarkers & Prevention*  
2002-2005 Associate Editor, *Clinical Cancer Research*

2006-present Member, *Journal of Clinical Oncology*

**Editorial Reviews**

*Breast Cancer Research and Treatment*  
*British Journal of Cancer*  
*Cancer*  
*Cancer Epidemiology, Biomarkers and Prevention* (Senior Editor)  
*Cancer Research*  
*Cell Growth & Differentiation*  
*Clinical Cancer Research* (Associate Editor)  
*European Journal of Cancer*  
*Gene*  
*Journal of Clinical Oncology*  
*Journal of the National Cancer Institute*  
*Oncogene*  
*Molecular and Cellular Biology*  
*Molecular Endocrinology*  
*Development*

**Other Professional Activities**

2003 – present Associate Director of Research  
Breast Center at Baylor College of Medicine  
1999 – present Director, Cancer Prevention and Risk Assessment Clinic  
Breast Center at Baylor College of Medicine  
1997-1999 Clinical Core Director for San Antonio Site, Texas Cancer Genetics Consortium  
1997-1999 Attending Physician, Cancer Prevention and Risk Assessment Clinic, Cancer Therapy and  
Research Center and the San Antonio Cancer Institute, University of Texas Health Science  
Center at San Antonio  
1995-1999 Medical Oncology Attending Physician  
University of Texas Health Science Center at San Antonio  
1995-1999 Medical Oncology Attending Physician  
Audie Murphy Veterans Hospital, San Antonio, Texas  
1991-1995 Attending Physician  
Clinical Center, National Cancer Institute  
National Institutes of Health, Bethesda, Maryland  
1991-1995 Medical Oncology Consultant  
Department of Internal Medicine, National Navy Medical Center

**TEACHING ACTIVITIES**

2000-present Lecturer, Carcinogenesis Course, Baylor College of Medicine, Breast Center  
2000-present Lecturer, Translational Research Course, Breast Cancer Prevention  
Baylor College of Medicine, Breast Center  
2000-present Lecturer, Clinical Oncology Board Review Course, Familial Breast Cancer  
University of Texas M. D. Anderson Cancer Center  
1999-present Lecturer, Medical Student Review Course, Cancer Prevention

1998-1999 Baylor College of Medicine, School of Medicine  
Lecturer, Medical Student Medical Oncology Course  
University of Texas Health Science Center at San Antonio School of Medicine

1998-present Lecturer, Molecular Therapeutics Course  
Medical Oncology Fellowship Training Program  
MD Anderson Cancer Center

1996-1999 Course Coordinator and Instructor, Molecular Medicine Course  
Department of Molecular Medicine, School of Biomedical Sciences  
University of Texas Health Science Center at San Antonio

1996-1999 Clinical Oncology Fellowship Research Training Course  
Division of Medical Oncology  
University of Texas Health Science Center at San Antonio

1996-1999 Lecturer, Medical Oncology Fellowship Program  
Division of Medical Oncology  
University of Texas Health Science Center at San Antonio

1993-1995 Instructor, Cancer Prevention and Control Academic Course  
Division of Cancer Prevention and Control  
National Cancer Institute, NIH

1991-1995 Clinical Oncology Fellow Training Course  
Medical Oncology Fellowship Program  
National Cancer Institute, NIH

1991-1995 Medical Student Preceptor  
Department of Internal Medicine  
Uniformed Services University of the Health Sciences

### Medical School Courses

<u>Role</u>	<u>Time</u>	<u>Course</u>	<u>Lecture Title</u>	<u>Students</u>	<u>Year</u>
Lecturer	1 hr (yearly)	Cancer Prevention Elective	Cancer Prevention	Medical Students	2000-present
Lecturer	1 hr (yearly)	Molecular Carcinogenesis	Epidemiology	Graduate & Medical Students	2000-present
Lecturer	1 hr (yearly)	Molecular Carcinogenesis	Cancer Prevention	Graduate & Medical Students	2000-present

### Smart Program

<u>Role</u>	<u>Time</u>	<u>Course</u>	<u>Lecture Title</u>	<u>Students</u>	<u>Year</u>
Lecturer	1 hr (summer)	Smart Program	Cancer Prevention	Smart Students	2000-present
Mentor	Summer	Smart Program Mentor	Summer Fellowship	Smart Students	2000-present

### Medical Student Preceptorship

<u>Role</u>	<u>Time</u>	<u>Course</u>	<u>Students</u>	<u>Year</u>
Mentor	1 year	Medical Student Preceptor	Alexandro Contreras	2005

### Medical Student Research Training Program

<u>Role</u>	<u>Time</u>	<u>Course</u>	<u>Students</u>	<u>Year</u>
Lecturer	1 hr (yearly)	Cancer Prevention Research	Medical Students	2002-present

Mentor 1 year Fellowship Mentor Medical Student 2004-2005

## Graduate Students

### Mentor

<u>Date</u>	<u>Name</u>	<u>Role</u>	<u>Institution</u>
2005-present	Corey Speers	Thesis Advisor	Baylor College of Medicine
2003-present	Valerie Cuba	Thesis Advisor	Baylor College of Medicine
2000-2005	David Denardo	Thesis Advisor	Baylor College of Medicine
1999-2004	Kendal Wu	Thesis Advisor	Baylor College of Medicine
2004-present	Simeen Zubairy	Committee Member	Baylor College of Medicine
2003-present	Lynette Burks Hamilton	Committee Member	Baylor College of Medicine
2003-present	Abhinav Jain	Committee Member	Baylor College of Medicine
2000-2004	Lei Deng	Committee Member	UTHSCH
1995-1999	David Bearrs	Committee Member	UTHSCSA

### Rotation Students

<u>Date</u>	<u>Name</u>	<u>Institution</u>
2005	Corey Speers	MD, PhD Student, BCM
2004	Simeen Zubairy	Predoctoral Student, BCM
2004	Valerie Cuba	Predoctoral Student, BCM
2004	Janagi Thirugnanasampanthan	Predoctoral Student, BCM
2003	Zhe Sha	Predoctoral Student, BCM
2002	Trish Peters	MD, PhD Student, BCM
2002	Bill Krause	Predoctoral Student, BCM
2000	David Denardo	Predoctoral Student, BCM
2000	Mercy Chen	Predoctoral Student, BCM
1997-1999	Kendall Wu	Predoctoral Student, UTHSCSA

## Postdoctoral Fellow

<u>Date</u>	<u>Name</u>	<u>Current Position</u>
2006-present	Sean Humphries	Baylor College of Medicine
2005-present	Lu Chen	Baylor College of Medicine
2004-2005	Kendall Wu	Postdoctoral Fellow, Stanford University
2004-present	Tracy Strecker	Baylor College of Medicine
2004-present	Yuxin Li	Baylor College of Medicine
2003-present	Ivan Uray	Baylor College of Medicine
2001-present	Qiang Shen	Baylor College of Medicine
2002-2003	Hye-Sook Seo	Postdoctoral Fellow, MD Anderson Cancer Center
2000-2004	Chunhua Lu, MD, PhD	Baylor College of Medicine
1997-1999	Caesar Tin-U, MD	Private Practice, Oncologist, UTHSCSA, TX
1997-1999	John Ludes-Meyers, PhD	Postdoctoral Fellow, Senior Scientist, MD Anderson Cancer Center
1995-1999	LiMin Yang, PhD	Instructor, UTHSCSA, TX

1994-1996      Leia Smith, PhD      Assistant Professor, Colorado State University

### College Students

<u>Date</u>	<u>Name</u>	<u>Current Position</u>
2003-2005	Elizabeth Dupre	Federal Government Intern
2000-present	Sarah Duong	St. Thomas University
1999-2004	Sunita Pal	University of St. Thomas
1999-2000	Deborah Yang	Medical Student, BCM
1999-2003	Emily Steinbis	Medical Student, UT Southwestern
1999-2003	XiYang Huang	Medical Student, Texas Tech Med School

### Other

<u>Date</u>	<u>Name</u>	<u>Level</u>	<u>Current Position</u>
2001-2002	Gu Kong	Assistant Professor	Associate Professor, Hanyang University, Korea
1996-1997	Praveen Reddy, MD	Visiting Scientist	Medical Oncology Fellow

### PATENTS

Co-inventor, Dominant-negative deletion mutants of *c-Jun* and their use in the prevention and treatment of cancer. Case # 2026-4120, Patent Pending.

### GRANT SUPPORT

#### Current Grant Support

2004-2009	RO1 CA78480, NCI/NIH (Competative renewal now in year 8) P. Brown, Principal Investigator Molecular Mechanisms by which Rexinoids Prevent Breast Cancer
2003-2008	RO1 CA10121, NCI/NIH P. Brown, Principal Investigator Prevention of ER-Negative Breast Cancer: Identification of Biomarkers Associated with Successful Chemoprevention
2004-2005	Breast Cancer Research Foundation P. Brown, Principal Investigator Neoadjuvant Trial of GW572016 for the Treatment of Women With DCIS Breast Cancer
2002-2007	SPORE CA58183, NIH Breast Cancer SPORE Grant K. Osborne, Principal Investigator P. Brown, Project Leader Project 3: Prevention of Breast Cancer Using Signal Transduction Inhibitors
2001-2006	NSABP Prevention Main Member Grant, NCI/NIH P. Brown, Principal Investigator Cancer Prevention Clinical Trials

- 1999-2006 U19 Program Project  
P. Brown, Principal Investigator  
of Program and of Project #3  
Chemoprevention of Breast and Ovarian Cancer
- 1997-present SWOG CCOP Grant, NCI/NIH  
P. Brown, Site Principal Investigator for Cancer Prevention Studies  
Southwest Oncology Group
- 2004-2005 BCM Cancer Center  
P Brown, Principal Investigator  
Blockade of AP-1 Transcription Factor for the Prevention of  
ER-positive and ER-negative Breast Cancer

**Submitted Grants:**

- 2006 R01, NCI/NIH  
P. Brown, Principal Investigator  
Targeting AP-1/ER Crosstalk for the Prevention of Breast Cancer

**Previous Grant Support**

- 2003-2005 AstraZeneca Alliance Grant  
P. Brown, Principal Investigator  
Prevention of Breast Cancer Using Lox Inhibitors
- 2002-2004 Avon/NCI Breast Cancer Research  
P. Brown, Principal Investigator  
A Phase I/II Breast Cancer Prevention Study Using Iressa
- 1999-2004 R01 CA78480, NCI/NIH  
P. Brown, Principal Investigator  
Prevention of Breast Cancer Using Selective Retinoids
- 1999-2002 VA/DOD  
P. Brown, Co-Investigator  
The Modulation of Prostate Cancer Risk with Alpha-Tocopherol
- 1996-2001 DOD Breast Cancer Grant  
P. Brown, Principal Investigator  
Investigator Award  
Prevention of Breast Cell Transformation by Blockade Of  
The AP-1 Transcription Factor
- 1998-1999 Cancer Research Foundation of America  
P. Brown, Principal Investigator  
Mechanisms by Which Retinoids Prevent Breast Cancer
- 1998-1999 Prevention Member Grant (SWOG)  
P. Brown, Principal Investigator
- 1998-1999 Texas Cancer Genetics Consortium

- P. Brown, Clinical Core Director  
San Antonio Site
- 1996-1999 SPORE (NIH)  
C. K. Osborne, Principal Investigator  
P. Brown, Awardee  
Career Development Award
- 1996-1998 V Foundation for Cancer Research  
P. Brown, Principal Investigator  
Inhibition of Breast Cancer Cell Growth and  
Invasion Using AP-1 Transcription Factor Inhibitors
- 1995-1996 NIH (P50 CA58183)  
P. Brown, Principal Investigator  
SPORE in Breast Cancer, Pilot Study
- 1991-1995 Intramural NCI Research Program (Z01 CN000179)  
P. Brown, Principal Investigator
- 1979-1985 Medical Scientist Training Program (5T32GM07308-10)  
P. Brown, Principal Investigator

#### **CLINICAL TRIALS**

NSABP, STAR Breast Cancer Prevention Trial, Institutional Principal Investigator  
U19 Project 1, Chemoprevention of Breast Cancer, Co-Investigator  
U19 Project 2, Chemoprevention of Ovarian Cancer, Institutional Principal Investigator  
CGN, Ovarian Cancer Screening Trial, Institutional Principal Investigator  
SWOG, S0300, A Randomized Placebo-Controlled Biomarker Modulation Trial using Celecoxib in  
Premenopausal Women at High Risk for Breast Cancer, Study Coordinator  
Wise Breast Cancer Prevention Trial, Site Principal Investigator

#### **INVITED PRESENTATIONS**

Structure/Function Relationships of the *c-jun* Oncogene. Presented at the Oncology Research Conference, Division of Medical Oncology, Duke University Medical Center, 1991.

Mechanisms of Transformation by the *c-jun* Oncogene. Presented at the Sachler Research Conference, New York, 1992.

Biologic Mechanisms of Proposed Intervention Strategies. Presented at the Cancer Prevention and Control Academic Course, NIH, 1992.

Molecular Mechanisms of Chemopreventive Agents. Presented at the Cancer Prevention and Control Academic Course, NIH, 1993.

Biomarkers: Current and Future Prospects in Cancer Prevention. Third Annual Cancer Symposium on Cancer Prevention and Screening. Crozer Regional Cancer Center, PA, 1993.

Potential Uses of Transcription Factor Inhibitors in Cancer Prevention. University of California, San Francisco Clinical Oncology Research Conference, San Francisco, CA, 1993.

Potential Uses of Transcription Factor Inhibitors in Cancer Treatment and Prevention. University of Texas, San Antonio Division of Medical Oncology Research Conference, San Antonio, TX, 1994.

The Use of the Transcription Factor cJun as a Target for Novel Drug Development. NCI-COP Grand Rounds, NCI, NIH, Bethesda, MD, 1994.

Molecular Mechanisms of Chemopreventive Agents. Presented at the Cancer Prevention and Control Academic Course, NIH, 1994.

Role of the AP-1 Transcription Factor in Signal Transduction in Breast Epithelial Cells. Laboratory of Molecular Oncology Lecture Series, NCI, NIH, Frederick, MD, 1995.

Role of the AP-1 Transcription Factor in the Transformation of Rodent and Human Cells. The Bowman Gray School of Medicine Molecular Genetics Seminar Series. Wake Forest University, Winston-Salem, NC, 1995.

Transcription Factors as Potential Targets for the Treatment and Prevention of Breast Cancer. Medicine Grand Rounds, The University of Texas MD Anderson Cancer Center, Houston, TX, 1995.

Targeting AP-1 for the Treatment and Prevention of Breast Cancer. Brook Army Medical Center Oncology Conference, San Antonio, TX, 1996.

Cancer Prevention Strategies for the 1990s and Beyond. Medicine Grand Rounds, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 1996.

Breast Cancer Prevention and Screening. Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 1997.

Targeting Transcription Factors for the Prevention of Breast Cancer. Cancer Prevention Conference. The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1997.

Mechanisms by which Retinoids Prevent Breast Cancer. The University of Texas MD Anderson Cancer Center, Houston, TX, 1998.

Inherited Cancers and Genetics: What the Primary Physician Needs to Know. Texas Medical Association, San Antonio, TX, 1998.

HER-2/neu in Breast Cancer. The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1998.

Are You at Risk: Genes, Inheritance, and Cancer. American Cancer Society, San Antonio, TX, 1998.

Targeting Transcription Factors for the Prevention of Breast Cancer. Vanderbilt University, 1998.

Modeling Mammary Cancer in Mice. Jackson Laboratory, Bar Harbor, ME, 1999.

Promise and Pitfalls of Quantitative RT-PCR. University of Texas Health Science Center, Houston, TX, 2000.

Targeting Transcription Factors for the Prevention of Breast Cancer. Cancer Prevention Conference. The University of Texas M. D. Anderson Cancer Center – Science Park, Smithville, TX, 2000.

Genetics of Breast Cancer. The University of Texas M. D. Anderson Cancer Center Medical Oncology Board Review Course. Houston, TX, 2000.

Chemoprevention of Breast Cancer. University of Washington School of Medicine Breast Cancer Summit 2001.

Mentor for the Alamo Breast Cancer Foundation Patient Advocate Program, San Antonio, TX, 2001.

Vitamin E Induced Biomarkers. San Antonio, TX, 2002.

Novel Strategies for the Prevention of ER-Negative Breast Cancer. University of Nebraska Medical Center, Eppley Institute for Cancer Research, Omaha, Nebraska, 2002.

New Strategies to Prevent Breast Cancer. UT M.D. Anderson Cancer Center Thoracic Head and Neck Medical Oncology Group, Houston, TX, 2002.

Breast Cancer Prevention. Rice University Promise of Genetic Research: Preventing and Treating Disease. Houston, TX, 2002.

Novel Strategies for the Prevention of Breast Cancer. UT M.D. Anderson Cancer Center Department of Medicine Grand Rounds, Houston, TX, 2002.

Update on Breast Cancer Prevention Trials Using SERMs. TMC Women's Health Network presents Women's Health and Cancer Clinical Trials: What You Should Know. Houston, TX, 2002.

ER-Negative Cancer Prevention Meeting. NCI, Washington, DC, 2003.

New Strategies for the Prevention of Breast Cancer. AstraZeneca 2003 Breast Cancer Symposium, Boston, MA, 2003.

Mentor for Patient Advocate Program for the Alamo Breast Cancer Foundation, San Antonio, TX, 2003.

Novel Strategies for the Prevention of ER-Negative Breast Cancer. Kansas University Medical Center, 2004.

Advances in Prevention of Breast Cancer, AstraZeneca 2004 Breast Cancer Symposium, Boston, MA, 2004.

Mentor for Patient Advocate Program for the Alamo Breast Cancer Foundation, San Antonio, TX, 2004.

Mentor for Patient Advocate Program for the Alamo Breast Cancer Foundation, University of Virginia, 2005.

Novel Strategies for the Prevention of Breast Cancer, University of Virginia, Charlottesville, VA, 2005.

Novel Strategies for the Prevention of Breast Cancer, MD Anderson Cancer Center, Houston, TX, 2005.

Novel Strategies for the Prevention of Breast Cancer, UT Southwestern Evening of Experts, Dallas, TX, 2005.

Targeting Signal Transduction Pathways for the Prevention of Breast Cancer, Kansas University, Kansas City, KS, 2005

Prevention of Estrogen Receptor-Negative Breast Cancer, Vanderbilt University, Nashville, TN, 2006

**PRESENTATIONS AT NATIONAL MEETINGS**

"Dominant-negative" Mutations of the Proto-oncogene *c-jun*. Presented at the 81st Annual Meeting of the American Association for Cancer Research, 1991.

"Dominant-negative" Mutants of *c-jun* Prevent Oncogene-induced Transformation of Rat Embryo Cells. Presented at the Eighth Annual Meeting on Oncogenes, 1992.

"Dominant-negative" cJun Mutants Inhibit TPA/*ras*-induced Transformation Through Multiple Mechanisms. Presented at the 83rd Annual Meeting of the American Association for Cancer Research, 1993.

Transcription Factors as Potential Targets for the Treatment and Prevention of Breast Cancer. Eastern Cooperative Oncology Breast Biology Meeting, Washington, D.C., 1994.

Interference with Signal Transduction in Human Breast Cancer Cells by Inhibiting AP-1 Transcription Factor Activity. Presented at the Seventeenth Annual San Antonio Symposium on Breast Cancer, San Antonio, TX, 1994.

Minisymposium Moderator, Prevention of Breast Cancer. Twentieth Annual San Antonio Symposium on Breast Cancer, San Antonio, TX, 1997.

Cancer Chemoprevention. Presented at the Plenary Session of the Southwest Oncology Group meeting, Seattle, Washington, 1997.

Receptor-selective Retinoids Suppress Mammary Tumorigenesis in Transgenic Mice. Modeling Human Mammary Cancer in Mice, Jackson Laboratories, Bar Harbor, Maine, 1999.

Breast Cancer Chemoprevention. Presented at the Meet-the-Expert Sunrise Session of the 93<sup>rd</sup> Annual Meeting of the American Association for Cancer Research, San Francisco, CA, 2001.

Mini-symposium. Updated View of CP Agent Development Strategies. Presented at the DCP Process for Cancer Prevention Agent Development Meeting of the NIH, Tucson, AZ, 2001.

Chemoprevention of Breast Cancer. Presented at the University of Washington School of Medicine Breast Cancer Summit 2001, Seattle, WA, 2001.

Moderator, General Session II. 24th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 2001.

Early Events in Human Breast Cancer Development. NCI Mouse Models of Human Cancers Consortium and the Organ Systems Branch Meeting. Santa Fe, NM, 2002.

Breast Cancer Chemoprevention. Meet the Expert Sunrise Session, 93<sup>rd</sup> Annual AACR Meeting, San Francisco, CA, 2002.

Tyrosine Kinase Inhibitors in Cancer. Duke Oncology Consortium Emerging Issues in Thoracic Breast and Ovarian Oncology, White Sulphur Springs, WV, 2002.

Chemoprevention Drug Development: Testing Promising Agents for the Prevention of Breast Cancer. AACR Frontiers in Cancer Prevention Research Meeting, Boston, MA, 2002.

Targeting Growth Factor Pathways and Transcription Factors for Cancer Prevention. AACR Frontiers in Cancer Prevention Research Meeting, Boston, MA, 2002.

Novel Molecular Targets for Cancer Prevention. AACR Frontiers in Cancer Prevention Research Meeting, Boston, MA, 2002.

The Future of Cancer Prevention Interventions Using Genomics and Proteomics. 94<sup>th</sup> Annual Meeting of the American Association for Cancer Research, Washington, DC, 2003.

Mouse Models of Pre-malignant Breast Disease. AACR Advance in Breast Cancer Research Genetics, Biology and Clinical Implications, Huntington Beach, CA, 2003.

Breast Cancer Prevention: What's Next After SERMs? STAR Scientific Session of the NSABP Treatment Principals Meeting, Huntington Beach, CA, 2003.

New Strategies for the Prevention of Breast Cancer. AstraZeneca 2003 Breast Cancer Symposium, Boston, MA, 2003.

Targeting Growth Factors for Prevention. Breast SPORE Roundtable, Cambridge, MA, 2003.

Genetics, Risk Modeling, Molecular Targets for Chemoprevention, Clinical Prevention Trials, Behavioral Prevention Research, Science and Public Policy. AACR Frontiers in Cancer Prevention Research: Member of the Scientific Committee, Phoenix, AZ, 2003.

Cell Cycle Regulators – Targets for Therapy? Co-moderator Mini Symposium 1, San Antonio Breast Cancer Symposium, San Antonio, TX, 2003.

Risk Assessment and Prevention – Who Should Be Targeted?" ASBD's 28<sup>th</sup> Annual Symposium, Boston, MA, 2004

Prevention of Breast Cancer with Rexinoids: Precinical and Early Phase Clinical Studies. AACR Frontiers in Cancer Prevention Research, Seattle, WA, 2004.

How to Identify and Qualify an Imaging Endpoint for Prevention Studies. SCORE V Workshop, Rockville, MD, 2005.

Chemoprevention in Breast Cancer. Keystone Symposia, Monterey, CA, 2005

Breast Cancer Chemoprevention: Biomarker End-Point Trials, AACR 96<sup>th</sup> Annual Meeting, Anaheim, CA, 2005.

Novel Approaches to Chemoprevention Targets. Targeted Therapies for the Treatment of Breast Cancer Conference, Dana Point, CA, 2005

SERMS and Beyond: Novel Strategies for the Prevention of Breast Cancer. Update of the Management of Breast Cancer, Omaha, NE, 2006.

#### **PRESENTATIONS AT INTERNATIONAL MEETINGS**

Biology of Lung Cancer. Presented at the Lung Cancer Workshop Meeting of the International Association for the Study of Lung Cancer. Bethesda, MD, 1993.

Targeting Transcription Factors for the Prevention and Treatment of Breast Cancer. Presented at the Sixth Annual International Breast Cancer Think Tank Meeting, Curacao, 1996.

Transcription Factor Crosstalk in Breast Cancer. Presented at the Seventh Annual International Breast Cancer Think Tank Meeting, St. Lucia, 1997.

Mechanisms by which Retinoids Prevent Breast Cancer. Presented at the Eight Annual International Breast Cancer Think Tank Meeting, Tobago, 1998.

RXR and Its Partners: Novel Targets for the Prevention of Breast Cancer. Presented at the Ninth Annual International Breast Cancer Think Tank Meeting, St. Thomas, U. S. Virgin Islands, 1999.

Role Of AP-1 In Regulating Breast Cell Growth And Transformation. Presented at the Tenth Annual International Breast Cancer Think Tank Meeting, Cancun, Mexico, 2000.

Targeting Transcription Factors For Breast Cancer Prevention And Treatment. Presented at the Eleventh Annual International Breast Cancer Think Tank Meeting, Punta Canta, Dominican Republic, 2001.

Prevention of Estrogen Receptor-Negative Breast Cancer. Presented at the Breast Cancer Symposium: Think Tank 13, Aruba, 2003.

The Mouse in Preclinical Trials: Transgenic, Carcinogen-induced or Xenographs Models – Which to Use? Presented at the The 24<sup>th</sup> Congress of the International Association for Breast Cancer Research: Preclinical Models for Breast Cancer Research. Sacramento, CA, 2003.

Prevention of Estrogen Receptor Negative Breast Cancer. Presented at the CHS International Educational Conference on Cancer Prevention. Dead Sea, Israel, 2004.

Prevention of ER-Negative Breast Cancer: Preclinical and Early Phase Prevention Studies. Presented at the Cancer Prevention Workshop. Haifa, Israel, 2004.

Transcription Factor Crosstalk in Breast Cancer. Presented at the Breast Cancer Symposium: Think Tank 14, Curacao, 2005.

Novel Strategies for the Prevention of Breast Cancer. Presented at the Texas-United Kingdom Collaborative Research Initiative, Oxford University, Oxford, UK, 2006.

#### **INTERESTS**

- Cancer prevention
- Chemoprevention

- Cancer risk assessment through genetic screening
- Breast cancer
- Development of new chemopreventive agents
- Role of transcription factors in oncogenesis
- Drug development of cancer prevention agents

## BIBLIOGRAPHY

1. **Brown PH**, Mathis DM, Cone RE, Jones PP, Ponzio NM and Thorbecke GJ. Properties of reticulum cell sarcomas in SJL/J mice. VIII. Prominent role of RCS cell I-A antigens in the stimulation of syngeneic T cells. *Immunogenetics* 18:399-412, 1983.
2. **Brown PH** and Thorbecke GJ. Characterization of the molecules on SJL/J lymphomas which stimulate syngeneic T cells. *J Immunology* 135:3572-3580, 1985.
3. DeKruyff R, **Brown PH**, Thorbecke GJ and Ponzio NM. Characterization of SJL T cell clones responsive to syngeneic lymphoma (RCS): RCS specific clones are stimulated by activated B cells. *J Immunology* 135:3581-3586, 1985.
4. Kermani ES, Borad JC, **Brown PH** and Tunnell G. New psychopathological findings in AIDS. *J Clin Psychiatry* 46:240-241, 1985.
5. **Brown PH**, Coico RF and Thorbecke GJ. Proliferative responses of T cells from SJL-F1 and F1-SJL bone marrow chimeras to SJL lymphoma cells. *Cell Immunology* 98:18-27, 1986.
6. Ponzio NM, **Brown PH** and Thorbecke GJ. Host-Tumor interactions in the SJL lymphoma model. *International Rev Immuno.* 1:273-301, 1986.
7. **Brown PH**, Ingram C and Van der Horst C. Listeria monocytogenes brain abscess. *Rev Infectious Diseases* 13:768-769, 1991.
8. **Brown PH**, Mulshine JL, and Birrer MJ. Tumor initiators and promoters in lung cancer. *Lung Cancer Research Quarterly* 1:3-15, 1991.
9. Szabo E, Preis LH, **Brown PH**, and Birrer MJ. The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation. *Cell Growth & Diff* 2:475-482, 1991.
10. Alani R, **Brown PH**, Binetruy B, Dosaka H., Rosenberg RK, Angel P, Karin M, and Birrer MJ. The transactivating function of the cJun proto-oncoprotein is required for cotransformation of rat embryo cells. *Mol Cell Biology* 11:6286-6295, 1991.
11. Birrer MJ and **Brown PH**. Application of molecular genetics to the early diagnosis and screening of lung cancer. *Cancer Res* 52:2658-2664, 1992.
12. Birrer MJ, Alani R, Cuttitta F, Preis L, Sanders D, Siegfried JM, Szabo E, and **Brown PH**. Early events in the neoplastic transformation of respiratory epithelium. *J Natl Cancer Inst Mono* 13:31-37, 1992.
13. Mulshine JL, Linnoila RI, Treston AM, Scott FM, Quinn K, Avis I, Shaw GL, Jensen SM, **Brown P**, Birrer MJ, and Cuttitta F. Candidate biomarkers for application as intermediate end points of lung carcinogenesis. *J Cell Biochem.* 16G:183-186, 1992.
14. Mulshine JL, Treston AM, **Brown PH**, Birrer MJ, and Shaw GL. Initiators and promoters of lung cancer. *Chest* 103:4-11, 1993.

15. **Brown PH**, Alani R, Preis LH, Szabo E, and Birrer MJ. Suppression of oncogene-induced transformation by a deletion mutant of *c-jun*. *Oncogene* 8:877-886, 1993.
16. Kurie J, **Brown PH**, Salk E, Scheinberg D, Birrer M, Deutsch P, and Dmitrovsky E. Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation. *Differentiation* 54:115-122, 1993.
17. **Brown PH**, Chen T, Birrer MJ. Mechanism of action of a dominant-negative mutant of cJun. *Oncogene* 9:791-800, 1994.
18. Battey J, **Brown PH**, Gritz E, Hong WK, Johnson B, Karp D, Mulshine J, Shaw G, Shopland D, Sunday M., and Szabo E. Primary and secondary prevention of lung cancer. *Lung Cancer* 12:91-103, 1995.
19. Kim S, **Brown PH**, and Birrer MJ. The inhibitory activity of a transdominant *c-jun* mutant fused to the ligand binding domain of the estrogen receptor. *Oncogene* 12:1043-1053, 1996.
20. Chen TK, Smith LM, Gebhardt D, Birrer MJ, and **Brown PH**. Activation and Inhibition of the AP-1 Complex in Human Breast Cancer Cells. *Molecular Carcinogenesis* 15:215-226, 1996.
21. **Brown PH**, Kim S-H, Wise S, Sabichi AL, and Birrer MJ. Dominant negative mutants of cJun inhibit activity through multiple mechanisms and with different potencies. *Cell Growth and Differentiation* 7:1013-1021, 1996.
22. Zhao B, Yu W, Qian M, Simmons-Mechanica M, **Brown PH**, Birrer MJ, Sanders BG, and Kline K. Induction of apoptosis by RRR-alpha-tocopherly succinate in human breast cancer cells involved AP-1. *Molecular Carcinogenesis* 19:180-190, 1997.
23. Smith LM, Birrer MJ, Stampfer MR and **Brown PH**. Breast cancer cells have a lower AP-1 activity than normal human mammary epithelial cells. *Cancer Research* 57:3046-3054, 1997.
24. Yang L-M, Kim H-T, Munoz-Medellin D, Reddy P and **Brown PH**. Induction of retinoid resistance in breast cancer cells by overexpression of cJun. *Cancer Research* 57:4652-4661, 1997.
25. Osborne CK, Elledge RM, **Brown PH**, Hilsenbeck SG. BRCA1 in clinical breast cancer. *Breast Disease* 10:77-88, 1998.
26. Yu W, Simmons-Menchaca, M, You H, **Brown P**, Birrer M, Sanders B, Kline K. RRR-alpha-tocopheryl succinate induces prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. *Molecular Carcinogenesis* 22:247-257, 1998.
27. Yang L, Munoz-Medellin D, Kim H-T, Ostrowski J, Reczek P, and **Brown PH**. Retinoic acid receptor antagonist BMS453 inhibits the growth of normal and malignant breast cells without activating RAR-dependent gene expression. *Breast Cancer Research and Treatment* 56: 277-291, 1999.
28. Smith LM, Wise SC, Hendricks DT, Sabichi AL, **Brown PH**, and Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. *Oncogene* 18:6030-6070, 1999.
29. Yang L-M, Tin-U C, Wu K, and **Brown PH**. Role of retinoid receptors in the prevention and treatment of breast cancer. *J Mammary Gland Biol and Neoplasia* 57: 275-289, 1999.

30. Lippman SM and **Brown PH**. Tamoxifen prevention of breast cancer: an instance of the fingerpost. *J Natl Cancer Inst* 91:1809-1819, 1999.
31. Lippman SM and **Brown PH**. Re: Tamoxifen prevention of breast cancer: an instance of the fingerpost. (Commentary) *J Natl Cancer Inst* 92:657-660, 2000.
32. **Brown PH** and Lippman SM. Chemoprevention of breast cancer. *Breast Cancer Research and Treatment* 62:1-17, 2000.
33. Wu K, Kim H-T, Yang L-M, Tin-U C, Ludes-Myers J, Munoz-Medellin D, and **Brown PH**. 9-cis retinoic acid suppresses mammary tumorigenesis in C3(1)-Simian virus 40 T antigen-transgenic mice. *Clinical Cancer Research* 6:3696-3704, 2000.
34. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, Lawrence R, Deneke S, Herrera R, Fuqua SAW, **Brown P**, Osborne CK. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. *J Natl Cancer Inst* 92:1926-34, 2000.
35. Ludes-Meyers J, Liu Y, Munoz-Medellin D, Hilsenbeck S, and **Brown P**. AP-1 blockade inhibits the growth of normal and malignant breast cells. *Oncogene* 20:2771-2780, 2001.
36. Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D., Barr FG, Diab SG, **Brown PH**, Fuqua SA, and Osborne CK. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. *J Biological Chemistry* 276:27907-12, 2001.
37. Yang L, Ostrowski J, Reczek P and **Brown P**. The retinoic acid receptor antagonist, BMS453, inhibits normal breast cell growth by inducing active TGF $\beta$  and causing cell cycle arrest. *Oncogene* 20:8025-8035, 2001.
38. Wu K, Liu Y, **Brown P**. Retinoids in breast cancer prevention. *J Women's Cancer* 3:97-108, 2001.
39. You H, Yu W, Munoz-Medellin-D, **Brown PH**, Sanders BG, and Kline K. Role of extracellular signal-regulated kinase pathway in RRR- $\alpha$ -tocopheryl succinate-induced differentiation of human MDA-MB-435 breast cancer cells. *Molecular Carcinogenesis* 33:228-236, 2002.
40. Wu K, Kim H-T, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu X-C, Lamph WW, Kuhn JG, Green JE, and **Brown PH**. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD 1069. *Cancer Epidemiology Biomarkers and Prevention* 11:467-474, 2002.
41. Shah S, Pishvaian MJ, Easwaran V, **Brown PH**, and Byers SW. The role of cadherin  $\beta$ -catenin, and AP-1 in retinoid-regulated carcinoma cell differentiation and proliferation. *J Biol Chem* 277:25313-25322, 2002.
42. Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim H-T, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK, and **Brown PH**. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. *Oncogene* 21:7680-7689, 2002.
43. Kavanaugh CJ, Desai KV, Calvo A, **Brown PH**, Couldrey C, Lubet R and Green JE. Pre-clinical applications of transgenic mouse mammary cancer models. *Transgenic Research* 11:617-633, 2002.
44. Wu K, Zhang Y, Xu, X-C, Hill J, Celestino J, Kim H-T, Mohsin SK, Hilsenbeck SG, Lamph WW, Bissonette R, and **Brown PH**. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. *Cancer Research* 62:6376-6380, 2002.

45. Wu K and **Brown P**. Is low-dose tamoxifen useful for the treatment and prevention of breast cancer? *J Natl Cancer Inst* 95:766-767, 2003.
46. Schiff R, Chamness GC and **Brown PH**. Advances in breast cancer treatment and prevention: Aromatase inhibitors and new SERMs. *Breast Cancer Research* 5:228-231, 2003.
47. Shen Q and **Brown PH**. Novel agents for the prevention of breast cancer: Targeting transcription factors and signal transduction pathways. *J Mammary Gland Biol Neoplasia* 8:45-73, 2003.
48. Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, **Brown PH**. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. *J Natl Cancer Inst* 95:1825-1833, 2003.
49. Lu, C, Mohsin S, Hilsenbeck, S., Wakeling A, **Brown PH**. Re: Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors. *J Natl Cancer Inst* 96:715-717, 2004.
50. Kramer R and **Brown PH**. Should Tamoxifen Be Used in Breast Cancer Prevention? *Drug Safety*, 27:979-989, 2004.
51. Liu Y, Lu C, Shen Q, Munoz-Medellin D, Kim H, **Brown PH**. AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin dependent kinase activity. *Oncogene* 23:8238-46, 2004.
52. Allred DC, **Brown P**, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. *Breast Cancer Research* 6:240-245, 2004.
53. Kalidas M, Hilsenbeck S, **Brown P**. Defining the role of raloxifene for the prevention of breast cancer. *J Natl Cancer Inst* 96: 1731-1733, 2004.
54. Denardo DG, Kim HT, Hilsenbeck S, Cuba V, Tsimelzon A, **Brown PH**. Global gene expression analysis of ER transcription factor cross-talk in breast cancer: Identification of estrogen-induced/AP-1-dependent genes. *Molecular Endocrinology*, 19: 362-378, 2005
55. **Brown, P**. Risk Assessment: Controversies and management of moderate- to high-risk individuals. *The Breast Journal*, 11: S11-S19, 2005.
56. Kong G, Kim H-T, Wu K, DeNardo D, Hilsenbeck SG, Xu X-C, Lamph WW, Bissonnette R, Dannenberg AJ, and **Brown PH**. The RXR-selective retinoid, LGD1069, down-regulates COX-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. *Cancer Research* 65:3562-3469, 2005.
57. Medina D, Kittrell FS, Hill J, Shepard A, **Brown P**. Tamoxifen inhibition of estrogen receptor-negative mammary tumorigenesis. *Cancer Research* 65:3493-3496, 2005.
58. Kalidas M, **Brown, P**. Aromatase inhibitors for the treatment and prevention of breast cancer. *Clinical Breast Cancer*, 6:27-37, 2005.
59. **Brown PH**, Rashid A. Cancer Prevention: The importance of accurate risk assessment. *Cancer Epidemiol, Biomarkers & Prevention*, 14:1357-1358, 2005.

60. Lu C, Shen Q, Kim H, Hilsenbeck S, **Brown P**. cFos is critical for MCF 7 breast cancer cell growth. *Oncogene*, 24:6516-6524, 2005.
61. Shen Q, **Brown P**. Transgenic mouse models for the prevention of breast cancer. *Mutation Research* 576:93-110, 2005
62. Wu K, DuPre E, Kim H, Tin-U CK, Bissonnette RP, Lamph WW and **Brown PH**. Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. *Breast Cancer Research and Treatment*,96:147-57, 2006.
63. Srinivas H, Xia D, Moore NL, Uray IP, Kim H, Ma L, Weigel NL, **Brown PH**, Kurie JM. Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. *Biochem J*, 395:653-62, 2006.
64. Seo H, DeNardo D, Jacquot Y, Laios I, Vidal D, Zambrana C, Leclercq G, **Brown P**. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlatos with their ability to activate ER alpha. *Breast Cancer Res Treat.* (in press) 2006.
65. Jang K-S, Han H, Paik S, **Brown PH**, Kong G. Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer. *Cancer Letters* (in press) 2006.
66. Shen Q, Zhang Y, Uray IP, Hill LJ, Kim HT, Lu C, Young MR, Gunther EJ, Hilsenbeck SG, Chodosh LA, Colburn NH, **Brown PH**. The AP-1 transcription factor regulates postnatal mammary gland development. *Developmental Biology* (in press) 2006.

### Manuscripts Submitted

1. Denardo DG, Kim HT, Wu K, Lee AV, **Brown PH**. Estrogen-induced breast cancer cell growth does not require estrogen receptor DNA Binding. Submitted to *Cancer Research*, 2006.
2. Kim HT, Kong G, DeNardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, **Brown PH**. Identification of Biomarkers Modulated by the RXR-Selective Retinoid, LGD1069, in Human Breast Cells using Oligonucleotide Arrays. Submitted to *Cancer Research* 2006.
3. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Glazer RI, **Brown PH**, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Dyke TV, Perou CM. Identification of conserved gene expression features across human and murine mammary tumors. Submitted to *Nature Genetics* 2006.
4. Cui X, Kim H-J, Kuitatse I, Kim HT, **Brown PH**, Lee AV. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via JNK/AP-1 signaling to regulate cell migration. Submitted to *Cancer Research* 2006
5. Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim HT, **Brown P**, Sporn MB. The combination of the rexinoid, LG100268, and a SERM, either

Arzoxifene or Acolbifene, synergize in the prevention and treatment of mammary tumors in an estrogen receptor negative model of breast cancer. Submitted to *Clinical Cancer Research*, 2006.

6. Li Y, **Brown PH**. Translational approaches for the prevention of ER-negative breast cancer. Submitted to *Eur J Cancer Prevention*, 2006.
7. Uray I, **Brown PH**. Prevention of Breast Cancer: Current State of the Science and Future Opportunities. Submitted to *Expert Opinion on Investigational Drugs*, 2006.
8. Rajkumar L, Kittrell FS, Guzman RC, **Brown PH**, Nandi S, Medina D. Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Submitted to *Cancer Research*, 2006.

## BOOK CHAPTERS

1. Mulshine JL, Shaw GL, Cuttitta F, Scott F, Avis I, Treston AM, Linnoila RI, Birrer M, **Brown P**, Gupta PK, and Tockman MS. Applications of biomarkers for lung cancer early detection. In: Accomplishments in Cancer Research, J. B. Fortner, F.E. Rhoads, eds. J.B. Lippincott Co., Philadelphia, PA, 204-218, 1993.
2. Sanders D, Sabichi AL, **Brown PH**, and Birrer MJ. Malignancies of the lung. In: The Molecular Basis of Medicine, CV Dang and AM Feldman, eds. Mosby Publishers, Chicago, IL, 1996
3. **Brown P**, Fuqua S and Allred C. Pathogenesis of Estrogen receptor positive and negative breast cancer. Contemporary Endocrinology: Endocrine Oncology, S. P. Ethier, ed. Humana Press Inc., Totowa, NJ, 49-68, 2000.
4. Rashid A. and **Brown P**. Genetic counseling and screening. In: Advanced Therapy of Breast Disease, (Second Edition), S.E. Singletary, G.L. Robb, G.N. Hortobagyi, eds. B.C. Decker, Inc., Hamilton, Ontario, Canada, 84-96, 2004.

**SELECTED PUBLISHED ABSTRACTS**

1. **Brown PH**, Cone RE, Ponzio NM, Jones PP and Thorbecke GJ. Nature of T cell-stimulating molecules on SJL/J mouse lymphomas. *Federation Proceedings* 42:1195, 1983.
2. **Brown PH** and Thorbecke GJ. Role of highly glycosylated I-A molecules on SJL/J reticulum cell sarcomas (RCS) in the stimulation of syngeneic T cells. *Federation Proceedings* 43:1733, 1984.
3. Coico RF, **Brown PH**, Stein KM, Hayama T and Thorbecke GJ. T cells from SJL-F1 chimeras fail to respond to I-As on SJL reticulum cell sarcoma. *Federation Proceedings* 43:1624, 1984.
4. Stein KM, **Brown PH**, Hayama T and Thorbecke GJ. Promotion of reticulum cell sarcoma (RCS) cell growth in vitro by lymphokines. *Federation Proceedings* 42:1932, 1984.
5. Lasky J, Feizi T, Scuderi J, **Brown P** and Thorbecke GJ. Glycosylated antigens on RCS involved in T cell stimulation. Sixth International Congress of Immunology, p.519, 1986.
6. Rozin S and **Brown PH**. Machine-like cardiac noise in a patient with rheumatic heart disease. 69th Annual Meeting of the American College of Physicians, 1988.
7. **Brown PH**, and Birrer M. "Dominant-negative" mutations of the proto-oncogene *c-jun*. *Proc Am Assoc Cancer Res* 31:312, 1990.
8. **Brown PH**, Binetruy B, Alani R, Rosenberg RK, Karin M, and Birrer MJ. Transforming and transcriptional activating domains of *c-jun* map to the same region. Sixth Annual Meeting on Oncogenes, Frederick, MD, p. 68, 1990.
9. Rosenberg RK, Dosaka H, **Brown P**, and Birrer MJ. Deregulated *c-jun* expression mimics the effects of TPA on primary mammalian cells. Sixth Annual Meeting on Oncogenes, Frederick, MD, p. 69, 1990.
10. **Brown PH**, Sanders DA, Alani R, and Birrer MJ. "Dominant-negative" mutants block the transforming effect of *c-jun*. *J. Cell. Biochem. suppl.* 15F:21, 1991.
11. **Brown PH**, Sanders DA, Alani R, and Birrer MJ. "Dominant-negative" mutants prevent *jun*-induced transformation. *Proc. Am. Assoc. Cancer Res.* 32:296, 1991.
12. Szabo E, Preis L, **Brown PH**, and Birrer MJ. The role of *jun* and *fos* gene family members in hematopoietic differentiation. *Proc. Am. Assoc. Cancer Res.* 32:287, 1991.
13. Sanders D, **Brown PH**, Preis L, Bynum BS, and Birrer MJ. Transformation of rat-1a cell line by *c-jun* correlates with transactivation of cellular genes. *Proc. Am. Assoc. Cancer Res.* 32:286, 1991.
14. Sanders D, **Brown PH**, Preis L and Birrer MJ. Transformation of rat-1a cell line by *c-jun* correlates with transactivation of cellular genes. Seventh Annual Meeting on Oncogenes, Frederick, MD, p. 401, 1991.
15. Sanders D, **Brown PH**, Preis L, and Birrer MJ. Inhibitors of the transforming activity of the *c-jun* proto-oncogene. *Proc Am Assoc. Cancer Res.* 33:370, 1992.

16. Kurie J, **Brown PH**, Salk E, Deutsch P, Birrer MJ, and Dmitrovsky E. Transient transfection of c-fos or c-jun augments retinoic acid receptor (RAR) response element activity in a human teratocarcinoma (TC) cell. *Proc Am Assoc Cancer Res* 33:374, 1992.
17. Domann FE, Levy JP, **Brown PH**, Birrer MJ, and Bowden GT. Stable expression of a dominant negative c-jun gene in malignant mouse epidermal cells blocks cellular AP-1 activity. *Proc Am Assoc Cancer Res* 33:190, 1992.
18. **Brown PH**, Kim S-H, Preis LH, and Birrer MJ. "Dominant-negative" mutants of c-jun prevent oncogene-induced transformation of rat embryo cells. Eighth Annual Meeting on Oncogenes, Frederick, MD, p. 303, 1992.
19. Sanders D, **Brown PH**, Preis L, and Birrer MJ. Inhibition of the transforming activity of the proto-oncogene c-jun. Eighth Annual Meeting on Oncogenes, Frederick, MD, p. 246, 1992.
20. **Brown PH**, Seigfried J, Nader L, Chen T, Szabo E, Sabichi A, Preis L, and Birrer M.. Effects of a dominant-negative inhibitor of c-jun on AP-1 activity in lung cancer cell lines. IASLC Lung Tumor Biology Workshop. *Lung Cancer* 42:18, 1993.
21. **Brown PH**, Kim S-H, Chen TK, Preis LH, and Birrer MJ. "Dominant-negative" cJun mutants inhibit TPA/ras-induced transformation through multiple mechanisms. *Proc Amer Assoc Cancer Res* 34:526, 1993.
22. **Brown PH**, Chen T, and Birrer MJ. "Dominant-negative" cJun mutants inhibit transactivation and transformation by quenching endogenous AP-1 activity. Ninth Annual Meeting on Oncogenes, Frederick, MD, p. 385, 1993.
23. Chen T, Birrer MJ, and **Brown PH**. Role of the AP-1 transcriptional activating complex in signal transduction in human breast cancer cells. Fourth Annual Meeting on The Molecular Basis of Cancer, Frederick, MD, p. 176, 1993.
24. Chen T, Birrer MJ, and **Brown PH**. Interference with signal transduction in human breast cancer cells using an inhibitor of the AP-1 transcriptional activating complex. *Pro. Am Assoc Cancer Res* 35:600, 1994.
25. Chen T, Gebhardt D, Birrer MJ, and **Brown PH**. Interference with growth factor-induced signal transduction in human breast cancer cells by inhibiting transcription factor activity. Fifth Annual Meeting on The Molecular Basis of Cancer, Frederick, MD, p. 52, 1994.
26. Smith LM, Chen TK, Birrer MJ, and **Brown PH**. Variation in growth factor-induced AP-1 activity in normal immortalized, and transformed human mammary epithelial cells. *Breast Cancer Res Treat* 32:56, 1994.
27. Smith LM, Birrer MJ, and **Brown PH**. Modulation of AP-1 activity in human mammary epithelial cells by growth factors and oncogenes. Eleventh Annual Meeting on Oncogenes, Frederick, MD, p. 218, 1995.

28. Smith LM, Birrer MJ, and **Brown PH**. Normal and transformed human mammary epithelial cells differ in the activity and inducibility of the AP-1 transcription factor. *Breast Cancer Research and Treatment* 37:61, 1995.
29. Birrer MJ, Sabichi AL, Wise S, Bober M, Smith LM, and **Brown PH**. Constitutive over-expression of cJun in human breast cancer cells is associated with decreased proliferation and tumorigenicity. *Proc Am Assoc Cancer Research* 37:533, 1996.
30. Birrer MJ, Sabichi AL, Wise S, Bober M, Smith LM, and **Brown PH**. Constitutive over-expression of cJun in human breast cancer cells is associated with morphologic change, decreased proliferation and altered gene expression. Twelfth Annual Meeting on Oncogenes, Frederick, MD, p. 256, 1996.
31. Yang, L-M., Gebhardt D, and **Brown PH**. Retinoids inhibit the AP-1 transcription factor in human breast epithelial cells. Sixth Annual Symposium on Cancer Research in San Antonio, p. 28, 1996.
32. Yang L-M, Gebhardt D, Kim H-T, Ostrowski J, Reczek P, and **Brown PH**. Differential effects of retinoids on proliferation and AP-1 activity in human breast epithelial cells. *Breast Cancer Research and Treatment* 41:267, 1996.
33. Wise SC, Smith LM, Hendricks DT, Sabichi AL, Bober M, **Brown PH**, and Birrer MJ. Over-expression of the cJun oncoprotein in the human breast cancer cell line MCF-7 results in tamoxifen resistance and increases invasiveness. *Proc Am Assoc Cancer Res* 38:173, 1997.
34. Yang, L-M, Kim H-T, Reddy P, Munoz-Medellin D, Ostrowski J, Reczek P, and **Brown PH**. Inhibition of breast cell growth by retinoids does not require activation of RARs. *Proc Am Assoc Cancer Res* 38:455, 1997.
35. Ludes-Meyers JH, Yang L-M, Munoz-Medellin D M, Kim HT, Hilsenbeck SG, and **Brown PH**. Normal human breast epithelial cells are more sensitive to AP-1 blockade than are breast cancer cells. *Breast Cancer Research and Treatment* 46:160, 1997.
36. Yu W, Birrer M J, **Brown PH**, Sanders BG, Kline K. RRR- $\alpha$ -tocopheryl succinate induces prolonged activation of c-jun in the induction of apoptosis in human MDA-MB-435 breast cancer cells. *Breast Cancer Research and Treatment* 46:278, 1997.
37. Yang L-M., Ludes-Meyer J, Munoz-Medellin D, Kim H-T, Reddy P, Ostrowski J, Reczek, P, **Brown PH**. Retinoid-induced growth suppression of normal human epithelial cells does not require activation of RAR-dependent gene transcription. *Breast Cancer Research and Treatment* 46:337, 1997.
38. Schiff R, Reddy P, Coronado E, Grim M, Hilsenbeck S, Fuqua S, **Brown PH**, Osborne CK. Development of tamoxifen-stimulated growth in vivo is associated with changes in AP-1 activity. *Breast Cancer Research and Treatment* 46:347, 1997.
39. Tin-U CK, Yang L-M, Wu K, Lamph W, Gottardis M, Ludes-Meyers J, Kim H-T, Munoz-Medellin D, **Brown PH**. Receptor-selective retinoids inhibit the growth of normal and malignant breast cells. *Proc of the Am. Society of Clin Oncol* 17:554, 1998.

40. Schiff R, Reddy P, Coronado E, Grim M, Herrera R, Hilsenbeck SG, Fuqua SAW, **Brown PH**, Osborne CK. Development of tamoxifen-stimulated growth *in vivo* is associated with an increase in AP-1 activity. 6th SPORE Investigators' Workshop, p. 11, 1998.
41. **Brown PH**, Wu K Tin-U C, Yang L-M, Hilsenbeck S, Green J, Lamph W, Gottardis M, Muñoz-Medellin D, Kim H-T. Suppression of breast carcinogenesis by receptor-selective retinoids. 6th SPORE Investigators' Workshop, p. 23, 1998.
42. Ludes-Meyers J, Yang L, Hilsenbeck S, Muñoz-Medellin D, **Brown PH**. Normal mammary epithelial cells are more dependent on AP-1 than are breast cancer cells. 8<sup>th</sup> Annual Symposium on Cancer Research in San Antonio, P. 15 (Abstr.18), 1998.
43. Wu K, Kim H-T, Yang L-M, Hilsenbeck S, Tin-U CK, Muñoz-Medelin D, Lamph WW, **Brown PH**. 9-cis retinoic acid prevents mammary tumorigenesis in C3(1)-SV40 T-antigen transgenic mice. 8th Annual Symposium on Cancer Research in San Antonio, p. 20 (Abstr. 39), 1998.
44. Yang L-M, Ludes-Meyers J, Munoz-Medellin D, Wu K, Tin-U C, Ostrowski J, Reczek P, **Brown PH**. Mechanisms by which retinoids inhibit normal breast cell growth. 8th Annual Symposium on Cancer Research in San Antonio, p. 20, 1998.
45. Schiff R, Ahotupa M, Reddy P, Coronado E, Hilsenbeck S, Fuqua SAW, Herrera R, **Brown PH**, Lawrence R, Deneke S, Osborne CK. Tamoxifen-stimulated breast tumor growth is associated with cellular oxidative stress and increased JNK activity. *Breast Cancer Res Treatment* 50:163, 1998.
46. Munoz-Medellin D, Ludes-Meyers J, Lee A, Yee D, **Brown PH**. Overexpression of cJun in MDA MB 435 human breast cancer cells inhibits their growth. *Breast Cancer Res Treatment* 50:258, 1998.
47. Yang L-M, Munoz-Medellin D, Ostrowski J, Reczek P, **Brown PH**. TGF $\beta$  mediates the inhibition of normal breast cell growth by the synthetic retinoid BMS453. *Breast Cancer Res Treatment* 50:276, 1998.
48. Wu K, Kim H-T, Tin-U CK, Yang L-M, Hilsenbeck S, Munoz-Medellin D, Lamph W, Gottardis M, **Brown PH**. Receptor-selective retinoids suppress mammary tumorigenesis in C3(1)-SV40 T-antigen transgenic mice. *Breast Cancer Res Treatment* 50:427, 1998.
49. Zhao H, Coronado-Heinsohn E, Seybold-Tilson K, Yang MC, Diab SG, Herrera RE, Yee D, **Brown PH**, Fuqua SAW, Osborne CK. Identification of FKHR as an estrogen receptor-interacting protein from tamoxifen-stimulated breast cancer. *Breast Cancer Res Treatment* 50:566, 1998.
50. Liu Y, Ludes-Meyers J, Munoz-Medellin D, Kim H-T, Zhang Y, Ge G, Schiff R, Osborne CK, and **Brown PH**. Inhibition of the AP-1 transcription factor suppresses the growth of MCF-7 breast cancer cells. 7<sup>th</sup> SPORE Investigators Workshop, 1999.
51. Wu K, Tin-U CK, Hilsenbeck SG, Bischoff ED, Lamph WW, Blumberg B, **Brown PH**. The RXR-selective retinoid, LGD1069, activates RXR-and PPAR-dependent pathways in breast cells. *Breast Cancer Res Treatment* 57:174, 1999.

52. Ludes-Meyers JH, Munoz-Medellin DM, Hilsenbeck SG, **Brown PH**. Growth factor-induced proliferation of breast cells requires AP-1 transactivation activity. *Breast Cancer Res Treatment* 57:465, 1999.
53. Liu Y, Ludes-Meyers J, Munoz-Medellin D, Kim H-T, Zhang Y, Ge G, Schiff R, Osborne CK, **Brown PH**. Inhibition of AP-1 suppresses the *in vitro* and *in vivo* growth of MCF-7 breast cancer. *Breast Cancer Res Treatment* 64:448, 2000.
54. Kim H-T, Liu Y, Munoz-Medellin D, **Brown PH**. Identification of AP-1 regulated genes in human breast cancer cells. *Breast Cancer Res Treatment* 64:455, 2000.
55. Liu Y, Ludes-Meyers J, Munoz-Medellin D, Kim H-T, and **Brown PH**. Breast cells require AP-1 transactivating activity for growth in response to peptide growth factors. DOD Era of Hope Breast Cancer Research Meeting, Atlanta, GA, 2000.
56. Wu K, Tin-U CK, Yang DJ, Lamph WW, **Brown PH**. The RXR-selective retinoid LGD1069 inhibits breast cell growth through cell cycle blockage and activation of other receptor pathways. *Breast Cancer Res Treatment* 64:572, 2000.
57. Wu K, Tin-U CK, Hilsenbeck SG, Bischoff ED, Lamph WW and **Brown PH**. The RXR-selective retinoids inhibit breast cell growth by inducing a G1 cell cycle block. *Proc Am Assoc Cancer Res* 41:1501, 2000.
58. Liu Y, Zhang J, Ludes-Meyers D, Munoz-Medelin H-T, Kim G, Schiff R, Osborne CK and **Brown PH**. AP-1 Blocked suppresses the *in vitro* and *in vivo* growth of MCF-7 breast cancer cells. *Proc Am Assoc Cancer Res* 42:128, 2001.
59. Kim H-T, Liu Y, Lu C, Munoz-Medellin D, and **Brown PH**. Identification of the genes regulated by AP-1 transcription factors in human breast cancer cells. *Proc Am Assoc Cancer Res* 42:626, 2001.
60. Lu C, Kim H-T, Lui Y, Medellin DM, and **Brown PH**. Identification of the dimerization partners of cJun dominant-negative mutant in breast cancer cells. *Proc Am Assoc Cancer Res* 42:627, 2001.
61. Celestino JC, Wu K, Zhang Y, Hilsenbeck SG, Lamp W, **Brown P**. 9-cis-retinoic acid suppresses mammary tumorigenesis in MMTV-ErbB2/Neu transgenic mice. *Breast Cancer Res Treatment* 69(3):226, 2001.
62. Lu C, Kim H, Liu Y, Munoz-Medellin D, **Brown P**. Identification of proteins associated with the AP-transcription factor that are critical for breast cancer growth. *Breast Cancer Res Treatment* 69(3):234, 2001.
63. Kim H, Munoz-Medellin D, Liu Y, Lu C, Hilsenbeck SG, **Brown PH**. Overexpression of cJun in breast cancer cells inhibits growth and induces cell death. *Breast Cancer Res Treatment* 69(3):273, 2001.
64. Wu K, Lamph WW, **Brown PH**. RXR-selective retinoids function independently of RAR and PPAR $\gamma$  to inhibit breast cell growth. *Breast Cancer Res Treatment* 69(3):274, 2001.

65. Lu C, Zhang Y, Hill J, Celestino J, Steinbis E, Bui D, Wu K, Kim H, Schiff R, Osborne K, Hilsenbeck S, Wakeling A, **Brown P**. Prevention of breast cancer in MMTV-ErbB2 transgenic mice using the tyrosine kinase inhibitor, ZD1839 ('Iressa'). *Breast Cancer Res Treatment* 76(1):19, 2002.
66. DeNardo DG, Kim HT, Lu C, Hilsenbeck S, **Brown PH**. Evidence for transcription factor cross-talk in breast cancer: identification of estrogen-induced AP-1-dependent genes. *Breast Cancer Res Treatment* 76(1):169, 2002.
67. Massarweh S, Shou J, DiPietro M, Mohsin SK, Hilsenbeck SG, Wakeling AE, **Brown PH**, Osborne CK, Schiff R. Targeting the epidermal growth factor receptor pathway improves the anti-tumor effect of tamoxifen and delays acquired resistance in a xenograft model of breast cancer. *Breast Cancer Res Treatment* 76(1):18, 2002.
68. Kim H-T, Kong G, DeNardo D, Pal S, Duong S, Hilsenbeck S, Bissonnette R, Lamph W, Johnson K, **Brown P**. Identification of genes regulated by the RXR-selective retinoid, LGD1069, in human breast cells using oligonucleotide arrays. *Breast Cancer Res Treatment* 76(1):184, 2002.
69. Shou J, Massarweh S, Mohsin SK, **Brown PH**, Wakeling AE, Ali AS, Osborne K, Schiff R. Blockade of the estrogen receptor/growth factor cross-talk implicated in breast cancer tamoxifen resistance using a selective EGFR TK inhibitor. *Breast Cancer Res Treatment* 76(1):246, 2002.
70. Shen Q, Liu Y, Lu C, Munoz-Medellin D, Kim H, Brown P. Mechanism by which AP-1 blockade inhibits growth and suppresses G1 cyclin expression in breast cancer cells. *Breast Cancer Res Treatment* 76(1):669, 2002.
71. Lu C, Kim H, Liu Y, Munoz-Medellin D, **Brown P**. cJun-dominant-negative mutant inhibits breast cancer cell growth by inactivating critical cJun partners. *Proc Am Assoc Cancer Res* 43:546, 2002.
72. Kong G, Kim H-T, Denardo D, Hilsenbeck S, Lamph WW, **Brown PH**. RXR-selective retinoid (LGD1069) down-regulates cyclooxygenase-2 (COX-2) expression in human normal and malignant breast cells: Implications for cancer chemoprevention. *Proc Am Assoc Cancer Res* 43:824, 2002.
73. Kim H-T, Kong G, Denardo D, Hilsenbeck S, Lamph WW, Johnson K, **Brown PH**. Identification of biomarkers modulated by the RXR-selective retinoid, LGD 1069, in human breast cells using cDNA microarrays. *Proc Am Assoc Cancer Res* 43:824, 2002.
74. Wu K, Zhang Y, Celestino J, Mohsin S, Hilsenbeck S, Lamph WW, **Brown PH**. The RXR-selective retinoid LGD1069, prevents tumor development in MMTV-erbB2 transgenic mice. *Proc Am Assoc Cancer Res* 43:1007, 2002
75. DeNardo D, Kim H, Tsimelzon A, Hilsenbeck SG, **Brown P**. Reverse promoter analysis: Identification of genes co-regulated by ER and AP-1 transcription factors using oligonucleotide microarrays. *Proc 11<sup>th</sup> SPORE Investigators' Workshop* #068, July 8-10, 2003.
76. Lu C, Qiang S, Kim H, DeNardo D, Wu K, **Brown P**. AP-1 blockade inhibits breast cancer cell growth by preventing the recruitment of coactivators. *Proc Am Assoc Cancer Res* 44:2378, 2003.

77. **Brown PH.** Targeting growth factors for prevention. NCI Breast SPORE Roundtable Meeting, Cambridge, MA, 2003.
78. Shen Q, Lu C, Liu Y, DeNardo D, Kim H-T, **Brown PH.** AP-1 blockade inhibits growth and suppresses G1 cyclin expression in breast cancer cells. *Proc Am Assoc Cancer Res* 44:3195, 2003.
79. DeNardo DG, Kim H-T, Hilsenbeck S, Tsimelzon A, Lu C, Shen Q, **Brown PH.** Identification of estrogen-induced, AP-1 dependent genes by global expression profiling. *Proc Am Assoc Cancer Res* 44:5064, 2003.
80. **Brown PH.** The mouse in preclinical trails: transgenic, carcinogen-induced, or Xenograph models – which to use? Presented at the 24<sup>th</sup> Congress on Breast Cancer Research: Advances in Human Breast Cancer Research: Preclinical Models for Breast Cancer Research, 2003. *Proc 12<sup>th</sup> SPORE Investigators' Workshop*, July 10-13, 2004.
81. Seo H-S, Kim H-T, Kong G, Desprez P-Y, Lamph WW, Johnson KA, **Brown PH.** Rexinoid-regulated biomarkers: Up-regulation of Id-1 correlates with rexinoid-induced growth suppression of normal and malignant breast cells. *Breast Cancer Res Treatment* 82:S115, 2003.
82. DeNardo DG, Kim HT, Thorn CA, Wu K, Lee AV, **Brown PH.** Estrogen's ability to stimulate breast cancer growth does not require ER DNA binding. *Breast Cancer Res Treatment* 82:S169, 2003.
83. Mohsin SK, Elledge RM, Arun B, Miller A, Wu K, Johnson K, Lamph WW, **Brown PH.** Breast cancer prevention using RXR-selective retinoid (Targretin®) in high risk women – initial report of a phase II randomized clinical trial. *Breast Cancer Res Treatment* 82:S176, 2003.
84. Shen Q, Lu C, Hill J, Zhang Y, Kim H-T, Young M, Colburn N, **Brown PH.** Targeting transcription factor AP-1 for the prevention of breast cancer. Proceedings of the AACR Frontiers in Cancer Prevention Research. *Cancer Epidemiology, Biomarkers & Prevention* 12:1345s, 2003.
85. Seo, H-S, Kim H-T, Kong G, Dupre E, Lamph WW, Johnson KA, **Brown PH.** Rexinoid-regulated biomarkers: Up-regulation of IGFBP-6 correlates with rexinoid-induced growth suppression of normal and malignant breast cells. Proceedings of the AACR Frontiers in Cancer Prevention Research. *Cancer Epidemiology, Biomarkers & Prevention* 12:1345s, 2003.
86. Kim H-T, Kong G, Pal S., Xiao-Chun X, Mohsin, S, Hilsenbeck, S, Lamph, W, Johnson, K, **Brown PH.** Biomarkers associated with successful prevention of breast cancer: Validation of rexinoid-regulated biomarkers in mouse and human mammary cells. Proceedings of the *Proc Am Assoc Cancer Res* 45:935, 2004.
87. Lu C, Speers C, Zhang Y, Xu X, Hill J, Kim H, Hilsenbeck S, Mohsin S, Wakeling A, Osborne CK, **Brown P.** The EGFR inhibitor Gefitinib (Iressa) prevents the development of ER-negative premalignant lesions and invasive mammary cancers in MMTV-erbB2 mice. *Proc 12<sup>th</sup> SPORE Investigators' Workshop*, July 10-13, 2004.
88. **Brown P,** Wu K, Mohsin S, Hilsenbeck SG, Lamph W, Johnson K, Elledge R. Prevention of breast cancer with rexinoids: Preclinical and early phase clinical studies. Proceedings of the AACR Frontiers in Cancer Prevention Research. *Cancer Epidemiology, Biomarkers & Prevention* 13, 2004.

89. Shen Q, Zhang Y, Hill J, Lu C, Kim H, Chodosh L, Young M, Colburn N, **Brown P**. Transcription factor blockade for mammary gland biology and prevention of breast cancer. Proceedings of the AACR Frontiers in Cancer Prevention Research. *Cancer Epidemiology, Biomarkers & Prevention* 13, 2004.
90. Shen Q, Lu C, Kim H-T, **Brown PH**. AP-1 blockade inhibits growth and suppresses G1 cyclin expression via down-regulation of E2F in breast cancer cells. Proceedings of the 27<sup>th</sup> Annual San Antonio Breast Cancer Symposium. *Breast Cancer Research and Treatment* 88, 2004.
91. Rashid A, Rosado Z, Hilsenbeck S, **Brown P**. Medical management of individuals with a BRCA1 or BRCA2 variant of unknown significance genetic test result. Proceedings of the 27<sup>th</sup> Annual San Antonio Breast Cancer Symposium. *Breast Cancer Research and Treatment* 88, 2004.
92. Uray IP, Seo H-S, Kim H, William L, Johnson K, **Brown P**. IGFBP6: an RXR-induced mediator of breast cancer chemoprevention. Proceedings of the 27<sup>th</sup> Annual San Antonio Breast Cancer Symposium. *Breast Cancer Research and Treatment* 88, 2004.
93. Uray IP, Kim, HT, Seo, HS, Lamph, W, Johnson, K, **Brown, P**. Critical role of retinoic acid receptors in the induction of IGFBP-6 by the chemopreventive rexinoid LGD1069 (bexarotene). *Proceedings of the 96<sup>th</sup> Annual AACR Meeting* April 26-30, 2005.
94. Denardo DG, Kim HT, Wu K, Lee A, **Brown, PH**. Estrogen receptor DNA binding is not required for estrogen to induce breast cancer cell growth. *Proceedings of the 96<sup>th</sup> Annual AACR Meeting* April 26-30, 2005
95. Shen Q, Kim HT, Young M, Gunther E, Hilsenbeck S, Chodosh L, Colburn N, **Brown P**. AP-1 blockade *in vivo* suppresses development of mammary tumor in MMTV- erbB2 mice. 4<sup>th</sup> Annual AACR Cancer Prevention Meeting, Baltimore, MD, 2005.
96. Arun B, Mohsin S, Miller A, Isaacs C, Saxton K, Hilsenbeck S, Lamph W, Johnson K, **Brown P**, Elledge R. Acquisition of breast tissue in a biomarker modulation study using bexarotene in women at high risk of breast cancer. 2005 ASCO Annual Meeting Proceedings. *Journal of Clinical Oncology* 23, 2005.
97. Denardo DG, Kim HT, Wu K, Lee AV, **Brown PH**. Estrogen receptor stimulated breast cancer cell growth independent of DNA binding activity. *Proceedings of the 4<sup>th</sup> Era of Hope Meeting* June 8-11, 2005.
98. Uray I, Seo H, Kim H, Bissonnette R, Lamph W, Johnson K, **Brown P**. Critical role of retinoic acid receptors in the induction of IGFBP-6 by the chemopreventive rexinoid bexarotene (LGD1069). *Keystone Symposia*. September 2005
99. Li Y, Kim H, Uray I, Bissonnette R, Lamph B, Johnson K, **Brown P**. Identification of genes modulated by LGD1069, a rexinoid that prevents mammary tumorigenesis. *San Antonio Breast Cancer Symposium* San Antonio, TX, 2005.
100. Cuba VL, DeNardo DG, Hilsenbeck S, Brown PH. Estrogen-induced suppression of gene expression: mechanisms of down-regulation. *San Antonio Breast Cancer Symposium*. San Antonio, TX, 2005.

101. Qiang Shen, Hee-Tae Kim, Matthew R. Young, Edward J. Gunther, Susan G. Hilsenbeck, Lewis A. Chodosh, Nancy H. Colburn, and **Powel H. Brown**. Suppression of ER-negative Mammary Tumor Development in MMTV- erbB2 Mice by Blockade of AP-1 Transcription Factor. *Keystone Symposia: Molecular Targets for Cancer Prevention*. Tahoe City, CA, 2006.
102. Li Y, Hill J, Zhang Y, Kim H, Uray I, Bissonnette R, Lamph W, Johnson K, Brown P. Retinoids prevent the development of premalignant mammary lesions in MMTV-erbB2 mice. Proceedings of the 97<sup>th</sup> AACR Annual Meeting, 2006.
103. Chen L, Krisko TI, Brown PB. Blockade of mitogen-activated protein kinase (MAPK) signaling inhibits the proliferation of normal and malignant breast cells. Proceedings of the 97<sup>th</sup> AACR Annual Meeting, 2006.